


Stabilis



Magnesium sulfate



Noms commerciaux

Addex magnesium	Islande, Norvège, Suède
Addex magnesium sulfaatii	Finlande
Conducat	Mexique
Infu Magnesol	Iran
Magnefusin	Mexique
Magnesium sulfate	Arabie Saoudite, Australie, Belgique, Canada, Etats Unis d'Amérique, France
Magnesium sulphate	Grande Bretagne
Magneso solfato	Italie
Magnezium sulfat	Turquie
Magvital	Autriche
Solfato de magnesio	Argentine, Chili, Equateur, Pérou, Vénézuéla
Sulmetin	Espagne



Stabilité des solutions

		40 mg/ml	19-24°C		90			2356
	RL	40 mg/ml	19-24°C		90			2356
		40 mg/ml	19-24°C		90			2356
	RL	40 mg/ml	19-24°C		90			2356
	∅	200 mg/ml	22°C		30			2294
	∅	200 mg/ml	4-6°C		60			2294
	RL	100 mg/ml	-20°C		30			3301
	RL	100 mg/ml	2-6°C		30			3301
	RL	100 mg/ml	22-25°C		30			3301



Stabilité en mélange

		8 mg/ml	20-23°C		Granisetron hydrochloride : 0,5 mg/ml	4		57
		15,6 mg/ml	25°C		Heparin sodium : 50 UI/ml	14		2100
		30 mg/ml	24°C		Ciclosporin : 2 mg/ml	6		291
		10 & 20 mg/ml	25°C		Metronidazole : 2 mg/ml	20		630
		10 & 20 mg/ml	25°C		Cefamandole nafate : 5 mg/ml	20		630
		10 & 20 mg/ml	25°C		Cefazolin sodium : 5 mg/ml	20		630
		10 & 20 mg/ml	25°C		Piperacillin sodium : 5 mg/ml	20		630
		10 & 20 mg/ml	25°C		Cefoxitin sodium : 5 mg/ml	20		630
		10 & 20 mg/ml	25°C		Moxalactam : 5 mg/ml	20		630
		3,81 & 8,92 mg/ml	25°C		Calcium gluconate : 3,81 & 8,92 mg/ml	7		3268
		3,81 & 8,92 mg/ml	5°C		Calcium gluconate : 3,81 & 8,92 mg/ml	7		3268
		1,9 mg/ml	25°C		Cisplatine : 0,1 mg/ml Potassium chloride : 2,9 mEq/l	28		3183
		1 & 2 mg/ml	-15°C		Cisplatine : 0,05 & 0,2 mg/ml Mannitol : 18,75 mg/ml	30		1080
		1 & 2 mg/ml	25°C		Cisplatine : 0,05 & 0,2 mg/ml Mannitol : 18,75 mg/ml	48		1080
		1 & 2 mg/ml	4°C		Cisplatine : 0,05 & 0,2 mg/ml Mannitol : 18,75 mg/ml	4		1080
		2 mg/ml	25°C		Lidocaine hydrochloride : 455 mg/ml	168		4457
		2 mg/ml	40°C		Lidocaine hydrochloride : 455 mg/ml	168		4457



Compatibilités

	Magnesium sulfate : 6 mg/ml Acetylsalicylic acid lysinate : 10 mg/ml	4698
	Magnesium sulfate Acetylsalicylic acid lysinate	3838
	Magnesium sulfate : 20 mg/ml Aciclovir sodium : 5 mg/ml	336
	Magnesium sulfate : 20 mg/ml Aldesleukin : 0.0338 MUI/ml	36
	Magnesium sulfate : 100 mg/ml Amifostine : 10 mg/ml	3
	Magnesium sulfate : 16.67 >> 100 mg/ml Amikacin sulfate : 5 mg/ml	1047

		Magnesium sulfate : 1,5 mg/ml Amiodarone hydrochloride : 9 mg/ml		4698
		Magnesium sulfate : 500 mg/ml Amiodarone hydrochloride : 6 mg/ml		1611
		Magnesium sulfate : 6 mg/ml Amoxicillin sodium : 20.83 mg/ml		4254
		Magnesium sulfate : 500 mg/ml Amoxicillin sodium / clavulanic acid : 100/10 mg/ml		3824
		Magnesium sulfate : 2 & 4 mg/ml Amphotericin B : 0,04 & 0,08 mg/ml		682
		Magnesium sulfate : 100 mg/ml Amphotericin B cholesteryl sulfate complex : 0.83 mg/ml		921
		Magnesium sulfate : 16.67 >> 100 mg/ml Ampicillin sodium : 20 mg/ml		1047
		Magnesium sulfate : 10 & 20 mg/ml Ampicillin sodium : 5 mg/ml		630
		Magnesium sulfate : 0,5 mg/ml Atosiban : 0,75 mg/ml		4642
		Magnesium sulfate : 100 mg/ml Aztreonam : 40 mg/ml		99
		Magnesium sulfate Betamethasone sodium phosphate		3838
		Magnesium sulfate : 100 mg/ml Bivalirudin : 5 mg/ml		1713
		Magnesium sulfate Bleomycin sulfate		4154
		Magnesium sulfate Butorphanol tartrate		3838
		Magnesium sulfate : 500 mg/ml Caffeine : 10 mg/ml		3964
		Magnesium sulfate Calcium chloride		3838
		Magnesium sulfate Calcium glucoheptonate		3838
		Magnesium sulfate : 3,81 & 8,92 mg/ml Calcium gluconate : 3,81 & 8,92 mg/ml		3268
		Magnesium sulfate Calcium gluconate		3838
		Magnesium sulfate Calcium gluconate		3644
		Magnesium sulfate : 100 mg/ml Caspofungin acetate : 0,7 mg/ml		2247
		Magnesium sulfate : 40 mg/ml Caspofungin acetate : 0.5 mg/ml		2233
		Magnesium sulfate : 16.67 >> 100 mg/ml Cefalotin sodium : 20 mg/ml		1047
		Magnesium sulfate : 10 & 20 mg/ml Cefamandole nafate : 5 mg/ml		630
		Magnesium sulfate : 16.67 >> 100 mg/ml Cefamandole nafate : 20 mg/ml		1047
		Magnesium sulfate Cefamandole nafate		3546

		Magnesium sulfate : 16.67 >> 100 mg/ml Cefazolin sodium : 20 mg/ml		1047
		Magnesium sulfate : 10 & 20 mg/ml Cefazolin sodium : 5 mg/ml		630
		Magnesium sulfate : 100 mg/ml Cefiderocol sulfate tosylate : 20 mg/mL		4528
		Magnesium sulfate : 250 mg/ml Cefmetazole sodium : 100 mg/ml		93
		Magnesium sulfate : 16.67 >> 100 mg/ml Cefoperazone sodium : 20 mg/ml		1047
		Magnesium sulfate : 16.67 >> 100 mg/ml Ceforanide : 20 mg/ml		1047
		Magnesium sulfate : 16.67 >> 100 mg/ml Cefotaxime sodium : 20 mg/ml		1047
		Magnesium sulfate : 10 & 20 mg/ml Cefoxitin sodium : 5 mg/ml		630
		Magnesium sulfate : 16.67 >> 100 mg/ml Cefoxitin sodium : 20 mg/ml		1047
		Magnesium sulfate : 100 mg/ml Ceftaroline fosamil : 2,22 mg/ml		3249
		Magnesium sulfate : 100 mg/ml Ceftaroline fosamil : 2,22 mg/ml	RL	3249
		Magnesium sulfate : 100 mg/ml Ceftobiprole medocaril sodium : 2 mg/ml		2269
		Magnesium sulfate : 10 mg/ml Ceftobiprole medocaril sodium : 2 mg/ml	RL	2269
		Magnesium sulfate Ceftobiprole medocaril sodium		4650
		Magnesium sulfate : 100 mg/ml Ceftolozane / tazobactam : 10/5 mg/ml		3828
		Magnesium sulfate : 16.67 >> 100 mg/ml Chloramphenicol sodium succinate : 20 mg/ml		1047
		Magnesium sulfate Chloroquine phosphate		3838
		Magnesium sulfate : 30 mg/ml Ciclosporin : 2 mg/ml		291
		Magnesium sulfate : 240 mg/ml Ciprofloxacin lactate : 2 mg/ml		288
		Magnesium sulfate : 240 mg/ml Ciprofloxacin lactate : 2 mg/ml		288
		Magnesium sulfate : 500 mg/ml Ciprofloxacin lactate : 2 mg/ml		261
		Magnesium sulfate : 100 mg/ml Cisatracurium besylate : 0.1 >> 5 mg/ml		299
		Magnesium sulfate Cisplatin		3578
		Magnesium sulfate Clindamycin phosphate		3526
		Magnesium sulfate : 16.67 >> 100 mg/ml Clindamycin phosphate : 12 mg/ml		1047
		Magnesium sulfate Clindamycin phosphate		3838

		Magnesium sulfate : 9,6 mg/ml Clonidine hydrochloride : 0,018 mg/ml		2018
		Magnesium sulfate : 500 mg/ml Cloxacillin sodium : 100 mg/ml		3012
		Magnesium sulfate : 16.67 >> 100 mg/ml Co-trimoxazole : 0.8/40 mg/ml		1047
		Magnesium sulfate Dexamethasone sodium phosphate		3838
		Magnesium sulfate : 100 mg/ml Dexmedetomidine : 4 µg/ml		1712
		Magnesium sulfate Dimenhydrinate		2087
		Magnesium sulfate : 2 mg/ml Dobutamine hydrochloride : 1 mg/ml	 	1058
		Magnesium sulfate : 83,3 mg/ml Dobutamine hydrochloride : 0,17 mg/ml		1221
		Magnesium sulfate : 100 mg/ml Docetaxel : 0.9 mg/ml		1754
		Magnesium sulfate : 100 mg/ml Doripenem : 5 mg/ml	 	2262
		Magnesium sulfate : 100 mg/ml Doxorubicin hydrochloride liposome peg : 0.4 mg/ml		251
		Magnesium sulfate : 100 mg/ml Eravacycline : 0,6 mg/ml		4434
		Magnesium sulfate : 16.67 >> 100 mg/ml Erythromycin lactobionate : 5 mg/ml		1047
		Magnesium sulfate : 100 mg/ml Etoposide phosphate : 5 mg/ml		1410
		Magnesium sulfate : 100 mg/ml		1415
		Magnesium sulfate : 16.67 >> 100 mg/ml Doxycycline hyclate : 1 mg/ml		1047
		Magnesium sulfate : 600 mg/ml Enalaprilate : 0.05 mg/ml		1315
		Magnesium sulfate Ergotamine tartrate		3838
		Magnesium sulfate : 10 mg/ml Esmolol hydrochloride : 10 mg/ml		384
		Magnesium sulfate Etoposide phosphate		3838
		Magnesium sulfate : 100 mg/ml Famotidine : 2 mg/ml		215
		Magnesium sulfate : 100 mg/ml Famotidine		397
		Magnesium sulfate : 100 mg/ml Fenoldopam mesylate : 80 µg/ml		1803
		Magnesium sulfate : 100 mg/ml Fludarabine phosphate : 1 mg/ml		492
		Magnesium sulfate Fludarabine phosphate		3838
		Magnesium sulfate Folate calcium		3838

		Magnesium sulfate Fosaprepitant dimeglumine		2295
		Magnesium sulfate : 100 mg/ml Fosfomycin : 30 mg/ml		4055
		Magnesium sulfate : 6 mg/ml Furosemide : 10 mg/ml		4698
		Magnesium sulfate		3838
		Magnesium sulfate : 200 mg/ml Furosemide : 10 mg/ml		3210
		Magnesium sulfate : 200 mg/ml Gallium nitrate : 1 mg/ml		91
		Magnesium sulfate : 16.67 >> 100 mg/ml Gentamicin sulfate : 0.8 mg/ml		1047
		Magnesium sulfate : 5 mg/ml Heparin sodium : 1 UI/ml	RL	1228
		Magnesium sulfate : 15.6 mg/ml Heparin sodium : 50 UI/ml		2100
		Magnesium sulfate : 5 mg/ml Heparin sodium : 1 UI/ml		1228
		Magnesium sulfate : 100 mg/ml		301
		Magnesium sulfate : 100 mg/ml Granisetron hydrochloride : 0.05 mg/ml		182
		Magnesium sulfate : 48.1 mg/ml		3948
		Magnesium sulfate : 16 mg/ml Granisetron hydrochloride : 1 mg/ml		57
		Magnesium sulfate : 100 mg/ml Hetastarch : 60 mg/ml		1721
		Magnesium sulfate Hydrocortisone sodium succinate		3838
		Magnesium sulfate : 500 mg/ml Hydrocortisone sodium succinate : 1 mg/ml	RL	1228
		Magnesium sulfate : 48.1 mg/ml		3948
		Magnesium sulfate : 500 mg/ml	RL	4603
		Magnesium sulfate : 500 mg/ml Hydrocortisone sodium succinate : 1 mg/ml		1228
		Magnesium sulfate : 16,67 >> 100 mg/ml Hydromorphone hydrochloride : 2 mg/ml		517
		Magnesium sulfate : 2 mg/ml Idarubicin hydrochloride : 1 mg/ml		491
		Magnesium sulfate : 200 mg/ml Imipenem-Cilastatin / Relebactam : 5 mg/ml		4433
		Magnesium sulfate : 40 mg/ml Insulin : 0.2 UI/ml		129
		Magnesium sulfate : 20 & 100 mg/ml Insulin aspart : 1 UI/ml		1508
		Magnesium sulfate : 100 mg/ml Isavuconazonium sulfate : 1.5 mg/ml		3829
		Magnesium sulfate : 500 mg/ml Ketamine hydrochloride : 50 mg/ml		2109

		Magnesium sulfate : 10 mg/ml Labetalol hydrochloride : 1 mg/ml		386
		Magnesium sulfate : 100 mg/ml Lansoprazole : 0,55 mg/ml		1625
		Magnesium sulfate : 20 mg/ml Levofloxacin : 5 mg/ml		2335
		Magnesium sulfate Levofolinate calcium		3838
		Magnesium sulfate : 100 mg/ml Linezolid : 2 mg/ml		1925
		Magnesium sulfate : 1 mg/ml Meropenem : 1 & 20 mg/ml		266
		Magnesium sulfate : 500 mg/ml Meropenem : 50 mg/ml		4319
		Magnesium sulfate Metoprolol tartrate		3838
		Magnesium sulfate : 10 & 20 mg/ml Metronidazole : 2 mg/ml		630
		Magnesium sulfate : 16.67 >> 100 mg/ml Metronidazole : 5 mg/ml		1047
		Magnesium sulfate : 100 mg/ml Micafungin : 1.5 mg/ml		2108
		Magnesium sulfate : 80 mg/ml Milrinone lactate : 0.8 mg/ml		813
		Magnesium sulfate : 16.67 >> 100 mg/ml Minocycline hydrochloride : 0.2 mg/ml		1047
		Magnesium sulfate : 2 >> 8 mg/ml Morphine sulfate : 2 mg/ml		218
		Magnesium sulfate : 16,67 >> 100 mg/ml Morphine sulfate : 1 mg/ml		517
		Magnesium sulfate Morphine tartrate		3838
		Magnesium sulfate : 10 & 20 mg/ml Moxalactam : 5 mg/ml		630
		Magnesium sulfate : 16.67 >> 100 mg/ml Moxalactam : 20 mg/ml		1047
		Magnesium sulfate : 10 & 20 mg/ml Nafcillin sodium : 5 mg/ml		630
		Magnesium sulfate : 16.67 >> 100 mg/ml Nafcillin sodium : 20 mg/ml		1047
		Magnesium sulfate : 500 mg/ml Naloxone hydrochloride : 0.4 mg/ml		3408
		Magnesium sulfate : 3>>4,5 mg/ml Nefopam : 0,16 mg/ml		4698
		Magnesium sulfate : 600 mg/ml Nicardipine hydrochloride : 0.1 mg/ml	 	1490
		Magnesium sulfate Norepinephrine bitartrate		3838
		Magnesium sulfate Omadacycline		4720
		Magnesium sulfate : 100 mg/ml Ondansetron hydrochloride : 1 mg/ml		334

		Magnesium sulfate : 16.67 >> 100 mg/ml Oxacillin sodium : 20 mg/ml		1047
		Magnesium sulfate : 100 mg/ml Oxaliplatin : 0,5 mg/ml		1662
		Magnesium sulfate : 100 mg/ml Paclitaxel : 1.2 mg/ml		248
		Magnesium sulfate Pantoprazole sodium		2090
		Magnesium sulfate : 500 mg/ml Paracetamol : 10 mg/ml		4742
		Magnesium sulfate : 16.67 >> 100 mg/ml Penicillin G potassium : 0.1 MUI/ml		1047
		Magnesium sulfate : 10 & 20 mg/ml Penicillin G potassium		630
		Magnesium sulfate : 16,67 >> 100 mg/ml Pethidine hydrochloride : 10 mg/ml		517
		Magnesium sulfate : 30 mg/ml Phloroglucinol : 2,5 mg/ml		3791
		Magnesium sulfate : 16.67 >> 100 mg/ml Piperacillin sodium : 60 mg/ml		1047
		Magnesium sulfate : 10 & 20 mg/ml Piperacillin sodium : 5 mg/ml		630
		Magnesium sulfate : 100 mg/ml Piperacillin sodium / tazobactam : 40/5 mg/ml		81
		Magnesium sulfate : 100 mg/ml Plazomicin sulfate : 24 mg/ml		4145
		Magnesium sulfate Polymyxine B		3838
		Magnesium sulfate : 100 mg/ml Potassium chloride : 40 mEq/l	RL	1228
		Magnesium sulfate : 100 mg/ml Potassium chloride : 40 mEq/l		1228
		Magnesium sulfate Potassium phosphate		3781
		Magnesium sulfate : 500 mg/ml Potassium phosphate : 3 mmol/ml		4389
		Magnesium sulfate Potassium phosphate		3838
		Magnesium sulfate Potassium phosphate		3621
		Magnesium sulfate Procaine hydrochloride		3838
		Magnesium sulfate : 100 mg/ml Propofol : 10 mg/ml	∅	300
		Magnesium sulfate : 500 mg/ml Propofol		4524
		Magnesium sulfate : 100 mg/ml Propofol		4524
		Magnesium sulfate : 8 mg/ml Remifentanil hydrochloride : 120 µg/ml		3176
		Magnesium sulfate : 100 mg/ml Remifentanil hydrochloride : 25 & 250 µg/ml		59

		Magnesium sulfate : 500 mg/ml Salbutamol sulfate : 1 mg/ml	∅	3216
		Magnesium sulfate : 100 mg/ml Sargramostim : 10 µg/ml	▲	335
		Magnesium sulfate Sodium bicarbonate		3838
		Magnesium sulfate Sodium Phosphate		3838
		Magnesium sulfate : 500 mg/ml Sodium Phosphate : 3 mmol/ml		4389
		Magnesium sulfate : 72.24 mg/ml Sugammadex : 100 mg/ml	∅	3372
		Magnesium sulfate : 100 mg/ml Sulbactam/durlobactam : 15/15 mg/ml	▲	4801
		Magnesium sulfate Tedizolid phosphate		3838
		Magnesium sulfate Tedizolid phosphate		3753
		Magnesium sulfate : 100 mg/ml Tedizolid phosphate : 0.8 mg/ml	▲	3827
		Magnesium sulfate : 100 mg/ml Telavancin hydrochloride : 7.5 mg/ml	RL	3254
		Magnesium sulfate : 100 mg/ml Telavancin hydrochloride : 7.5 mg/ml	▲◆	3254
		Magnesium sulfate : 500 mg/ml Thiopental sodium : 25 mg/ml	▲	3767
		Magnesium sulfate : 100 mg/ml Thiotepa : 1 mg/ml	◆	249
		Magnesium sulfate : 16.67 >> 100 mg/ml Tobramycin sulfate : 0.8 mg/ml	◆	1047
		Magnesium sulfate : 100 mg/ml Valproic acid : 2 & 20 mg/ml	▲◆	4428
		Magnesium sulfate : 16.67 >> 100 mg/ml Vancomycin hydrochloride : 5 mg/ml	◆	1047
		Magnesium sulfate : 10 mg/ml Verapamil hydrochloride : 0.08 mg/ml	▲◆	1057
		Magnesium sulfate Vinorelbine tartrate		3838



Bibliographie

	Type	Source
3	Revue	Trissel LA, Martinez JF. Compatibility of amifostine with selected drugs during simulated Y-site administration. Am J Health-Syst Pharm 1995 ; 52: 2208-2212.
36	Revue	Alex S, Gupta SL, Minor JR, Turcovski-Corrales S, Gallelli JF, Taub D, Piscitelli SC. Compatibility and activity of aldesleukin (recombinant interleukin-2) in presence of selected drugs during simulated Y-site administration: Evaluation of three methods. Am J Health-Syst Pharm 1995 ; 52: 2423-2426.

57	Revue	Mayron D, Gennaro AR. Stability and compatibility of granisetron hydrochloride in IV solutions and oral liquids and during simulated Y-site injection with selected drugs. Am J Health-Syst Pharm 1996 ; 53: 294-304.
59	Revue	Trissel LA, Gilbert DL, Martinez JF, Kim MC. Compatibility of remifentanyl hydrochloride with selected drugs during simulated Y-site administration. Am J Health-Syst Pharm 1997 ; 54: 2192-2196.
81	Revue	Trissel LA, Martinez JF. Compatibility of piperacillin sodium plus tazobactam with selected drugs during simulated Y-site injection. Am J Hosp Pharm 1994 ; 51: 672-678.
91	Revue	Lober CA, Dollard PA. Visual compatibility of gallium nitrate with selected drugs during Y-site injection. Am J Hosp Pharm 1993 ; 50: 1208-1210.
93	Revue	Hutchings SR, Rusho WJ, Tyler LS. Compatibility of cefmetazole sodium with commonly used drugs during Y-site delivery. Am J Health-Syst Pharm 1996 ; 53: 2185-2188.
99	Revue	Trissel LA, Martinez JF. Compatibility of aztreonam with selected drugs during simulated Y-site administration. Am J Health-Syst Pharm 1995 ; 52: 1086-1090.
129	Revue	Smythe M, Malouf E. Visual compatibility of insulin with secondary intravenous drugs in admixtures. Am J Hosp Pharm 1991 ; 48: 125-126.
182	Revue	Trissel LA, Gilbert DL, Martinez JF. Compatibility of granisetron hydrochloride with selected drugs during simulated Y-site administration. Am J Health-Syst Pharm 1997 ; 54: 56-60.
215	Revue	Keyi X, Gagnon N, Bisson C, Desmarais M, LeBel M. Stability of famotidine in polyvinyl chloride minibags and polypropylene syringes and compatibility of famotidine with selected drugs. Ann Pharmacotherapy 1993 ; 27: 422-426.
218	Revue	Vogt C, Ruggaber S. Compatibility of magnesium sulfate and morphine sulfate in 0.9% sodium chloride injection. Am J Hosp Pharm 1993 ; 50: 2311.
248	Revue	Trissel LA, Martinez JF. Turbidimetric assessment of the compatibility of taxol with 42 other drugs during simulated Y-site injection. Am J Hosp Pharm 1993 ; 50: 300-304.
249	Revue	Trissel LA, Martinez JF. Compatibility of thiotepa (lyophilized) with selected drugs during simulated Y-site administration. Am J Health-Syst Pharm 1996 ; 53: 1041-1045.
251	Revue	Trissel LA, Gilbert DL, Martinez JF. Compatibility of doxorubicin hydrochloride liposome injection with selected other drugs during simulated Y-site administration. Am J Health-Syst Pharm 1997 ; 54: 2708-2713.
261	Revue	Percy LA, Rho JP. Visual compatibility of ciprofloxacin with selected components of total parenteral nutrient solutions during simulated Y-site injection. Am J Hosp Pharm 1993 ; 50: 715-716.
266	Revue	Patel PR. Compatibility of meropenem with commonly used injectable drugs. Am J Health-Syst Pharm 1996 ; 53: 2853-2855.
288	Revue	Cervenka P, Dejong DJ, Butler BL, Monzingo MD. Visual compatibility of injectable ciprofloxacin lactate with selected injectable drugs during simulated Y-site administration. Hosp Pharm 1992 ; 27: 957-958,961-962.

291	Revue	Nieforth KA, Shea BF, Souney PF, Scavone JM. Stability of cyclosporine with magnesium sulfate in 5% dextrose injection. Am J Hosp Pharm 1993 ; 50: 470-472.
299	Revue	Trissel LA, Martinez JF, Gilbert DL. Compatibility of cisatracurium besylate with selected drugs during simulated Y-site administration. Am J Health-Syst Pharm 1997 ; 54: 1735-1741.
300	Revue	Trissel LA, Gilbert DL, Martinez JF. Compatibility of propofol injectable emulsion with selected drugs during simulated Y-site administration. Am J Health-Syst Pharm 1997 ; 54: 1287-1292.
301	Revue	Trissel LA, Gilbert DL, Martinez JF, Baker MB, Walter WV, Mirtallo JM. Compatibility of parenteral nutrient solutions with selected drugs during simulated Y-site administration. Am J Health-Syst Pharm 1997 ; 54: 1295-1300.
334	Revue	Trissel LA, Tramonte SM, Grilley BJ. Visual compatibility of ondansetron hydrochloride with selected drugs during simulated Y-site injection. Am J Hosp Pharm 1991 ; 48: 988-992.
335	Revue	Trissel LA, Bready BB, Kwan JW, Santiago NM. Visual compatibility of sargramostim with selected antineoplastic agents, anti-infectives, or other drugs during simulated Y-site injection. Am J Hosp Pharm 1992 ; 49: 402-406.
336	Revue	Forman JK, Lachs JR, Souney PF. Visual compatibility of acyclovir sodium with commonly used intravenous drugs during simulated Y-site injection. Am J Hosp Pharm 1987 ; 44: 1408-1409.
384	Revue	Colucci RD, Cobuzzi LE, Halpern NA. Visual compatibility of esmolol hydrochloride and various injectable drugs during simulated Y-site injection. Am J Hosp Pharm 1988 ; 45: 630-632.
386	Revue	Colucci RD, Cobuzzi LE, Halpern NA. Visual compatibility of labetalol hydrochloride injection with various injectable drugs during simulated Y-site injection. Am J Hosp Pharm 1988 ; 45: 1357-1358.
397	Revue	Fong PA, Ward J. Visual compatibility of intravenous famotidine with selected drugs. Am J Hosp Pharm 1989 ; 46: 125-126.
491	Revue	Turowski RC, Durthaler JM. Visual compatibility of idarubicin hydrochloride with selected drugs during simulated Y-site injection. Am J Hosp Pharm 1991 ; 48: 2181-2184.
492	Revue	Trissel LA, Parks NPT, Santiago NM. Visual compatibility of fludarabine phosphate with antineoplastic drugs, anti-infectives, and other selected drugs during simulated Y-site injection. Am J Hosp Pharm 1991 ; 48: 2186-2189.
517	Revue	Letourneau M. Visual compatibility of magnesium sulfate with narcotic analgesics. Am J Hosp Pharm 1992 ; 49: 838-839.
630	Revue	Das Gupta V, Stewart KR. Stability of metronidazole and ten antibiotics when mixed with magnesium sulphate solutions. J Clin Hosp Pharm 1985 ; 10: 67-72.
682	Revue	Raymond GG, Davis RL. Physical compatibility and chemical stability of amphotericin B in combination with magnesium sulfate in 5% dextrose injection. Ann Pharmacotherapy 1991 ; 25: 123-126.
813	Revue	Akkermann SR, Zhang H, Mullins RE, Yaughn K. Stability of milrinone lactate in the presence of 29 critical care drugs and 4 IV solutions. Am J Health-Syst Pharm 1999 ; 56: 63-68.

921	Revue	Trissel LA, Gilbert DL, Martinez JF. Incompatibility and compatibility of amphotericin B cholesteryl sulfate complex with selected other drugs during simulated Y-site administration. Hosp Pharm 1998 ; 33: 284-292.
1047	Revue	Souney PF, Colucci RD, Mariani G, Campbell D. Compatibility of magnesium sulfate solutions with various antibiotics during simulated Y-site injection. Am J Hosp Pharm 1984 ; 41: 323-324.
1057	Revue	Cutie MR. Compatibility of verapamil hydrochloride injection with commonly used additives. Am J Hosp Pharm 1983 ; 40: 1205-1207.
1058	Revue	Kirschenbaum HL, Aronoff W, Piltz GW, Perentesis GP, Cutie AJ. Compatibility and stability of dobutamine hydrochloride with large-volume parenterals and selected additives. Am J Hosp Pharm 1983 ; 40: 1690-1691.
1080	Revue	La Folette JM, Arbus MH, Lauper RD. Stability of cisplatin admixtures in polyvinyl chloride bags. Am J Hosp Pharm 1985 ; 42: 2652.
1221	Revue	Dahlin PA, Paredes SM. Visual compatibility of dobutamine with seven parenteral drug products. Am J Hosp Pharm 1980 ; 37: 460,464.
1228	Revue	Allen LV, Stiles ML. Compatibility of various admixtures at Y-injection sites of intravenous administration sets. Part2. Am J Hosp Pharm 1981 ; 38: 380-381.
1315	Revue	Halpern NA, Colucci RD, Alicea M, Greenstein R. Visual compatibility of enalaprilat with commonly used critical care medications during simulated Y-site injection. Int J Pharm Clin Pharmacol Ther Tox 1989 ; 27: 294-297.
1410	Revue	Trissel LA, Martinez JF, Simmons M. Compatibility of etoposide phosphate with selected drugs during simulated Y-site injection. J Am Pharm Assoc 1999 ; 39: 141-145.
1415	Revue	Trissel L.A, Gilbert D.L, Martinez J.F, Baker M.B, Walter W.V, Mirtallo J.M. Compatibility of medications with 3-in-1 parenteral nutrition admixtures. JPEN 1999 ; 23: 67-74.
1490	Revue	Halpern NA, Colucci RD, Alicea M, Greenstein R. The compatibility of nicardipine hydrochloride injection with various ICU medications during simulated Y-site injection. Int J Pharm Clin Pharmacol Ther Tox 1989 ; 27: 250-254.
1508	Revue	Voirol P, Berger-Gryllaki M, Pannatier A, Eggimann P, Sadeghipour F. Visual compatibility of insulin aspart with intravenous drugs frequently used in ICU. EJHP 2015 ;22:123-124.
1611	Revue	Chalmers JR, Bobek MB, Militello MA. Visual compatibility of amiodarone hydrochloride injection with various intravenous drugs. Am J Health-Syst Pharm 2001 ; 58: 504-506.
1625	Revue	Trissel LA, Saenz C, Williams YW, Ingram D. Incompatibilities of lansoprazole injection with other drugs during simulated Y-site coadministration. Int J Pharm Compound 2001 ; 5: 314-321.
1662	Revue	Trissel LA, Saenz CA, Ingram DS, Ogundele AB. Compatibility screening of oxaliplatin during simulated Y-site administration with other drugs. J Oncol Pharm Practice 2002 ; 8: 33-37.
1712	Revue	Trissel LA, Saenz CA. Compatibility screening of Precedex during simulated Y-site administration with other drugs. Int J Pharm Compound 2002 ; 6: 230-233.
1713	Revue	Trissel LA, Saenz CA. Compatibility screening of bivalirudin during simulated Y-site administration with other drugs. Int J Pharm Compound 2002 ; 6: 311-315.

1721	Revue	Trissel LA, Williams KY, Baker MB. Compatibility screening of Hextend during simulated Y-site administration with other drugs. Int J Pharm Compound 2001 ; 5: 69-72.
1754	Revue	Trissel LA, Gilbert DL, Wolkin AC. Compatibility of docetaxel with selected drugs during simulated Y-site administration. Int J Pharm Compound 1999 ; 3: 241-244.
1803	Revue	Trissel, LA, Saenz CA, Ogundele OB, Ingram D, Baker MB. Compatibility of fenoldopam mesylate with other drugs during simulated Y-site administration. Am J Health-Syst Pharm 2003 ; 60: 80-85.
1925	Revue	Trissel LA , Williams KY, Gilbert DL. Compatibility screening of linezolid injection during simulated Y-site administration with other drugs and infusion solutions. J Am Pharm Assoc 2000 ; 40: 515-519.
2018	Revue	Veggeland T. Visual compatibility of clonidine with selected drugs. Am J Health-Syst Pharm 2005 ; 62: 1968-1969.
2087	Revue	Ferreira E, Forest JM, Hildgen P. Compatibility of dimenhydrinate injectable by Y administration. Pharmactuel 2004 ; 37: 17-20.
2090	Revue	Pere H, Chasse V, Forest JM, Hildgen P. Compatibility of injectable pantoprazole in Y-site administration. Pharmactuel 2004 ; 37: 193-196.
2100	Revue	Gervas S, Gosalbez F. Estabilidad fisica y quimica del sulfato magnesico combinado con heparina sodica en solucion salina al 0,9 por 100. Farm Hosp 1995 ; 19: 38-40.
2108	Revue	Trusley C, Kupiec TC, Trissel LA. Compatibility of micafungin injection with other drugs during simulated Y-site co-administration. Int J Pharm Compound 2006 ; 10: 230-232.
2109	Revue	Pelletier E, Forest JM, Hildgen P. Compatibilité de la kétamine injectable lors de l'administration en dérivé avec d'autres médicaments usuels. Pharmactuel 2006 ; 39: 71-75.
2233	Revue	Condie C.K, Tyler L.S, Barker B, Canann D.M. Visual compatibility of caspofungin acetate with commonly used drugs during simulated Y-site delivery Am J Health-Syst Pharm 2008 ; 65, 5: 454-457.
2247	Revue	Chan P, Heatherly K, Kupiec T.C, Trissel L.A. Compatibility of caspofungin acetate injection with other drugs during simulated Y-site coadministration. Int J Pharm Compound 2008 ; 12, 3: 276-278.
2262	Revue	Brammer MK, Chan P, Heatherly K, Trusley C, Kupiec TC, Trissel LA, Psathas PA, Gilmor T, Schaufelberger D. Compatibility of doripenem with other drugs during simulated Y-site administration Am J Health-Syst Pharm 2008 ; 65: 1261-1265.
2269	Revue	Chan P, Bishop A, Kupiec TC, Trissel LA, Gole D, Jimidar IM, Vermeersch H. Compatibility of ceftobiprole medocaril with selected drugs during simulated Y-site administration. Am J Health-Syst Pharm 2008 ; 65, 16: 1545-1551.
2294	Revue	Newby B.D, Benes C, Palmer L, Cleve R. Stability of magnesium sulfate 20% in Viaflex bags. Can J Hosp Pharm 2008 ; 61, 5: 356-357.
2295	Laboratoire	Fosaprepitant (Emend®) - Summary of Product Characteristics Merck Sharp Dohme 2013
2335	Revue	Canann D, Tyler L.S, Barker B, Condie C. Visual compatibility of i.v. medications routinely used in bone marrow transplant recipients Am J Health-Syst Pharm 2009 ; 66, 8: 727-729

2356	Revue	Sarver J.G, Pryka R, Alexander K.S, Weinstein L, Erhardt P.W. Stability of magnesium sulfate in 0.9% sodium chloride and lactated Ringers solutions. Int J Pharm Compound 1998 ; 2, 5: 385-388.
3012	Revue	Sullivan T, Forrest J.M, Leclair G. Compatibility of Cloxacillin Sodium with Selected Intravenous Drugs During Simulated Y-Site Administration Hosp Pharm 2015 ; 50, 3: 214-220.
3176	Poster	Humbert Delaloye V, Berger M, Voirol P, Pannatier A. Compatibilité du Remifentanyl avec d'autres médicaments injectables : influence du soluté. 16èmes JFSPH, Sion, 18-19 novembre 2010
3183	Revue	Sewell G Physical and chemical stability of cisplatin infusions in PVC containers. EJOP 2010 ; 4, 3: 11-13.
3210	Revue	Jasti Bhaskara R, Saraf Poonam. Compatibility of Parenteral Furosemide with Seventeen Secondary Drugs Used in Standard Concentrations. Int J Pharm Compound 2011 ; 15, 3: 259-261.
3216	Revue	Legris ME, Valiquette ME, Lavoie A, Forest JM, Leclair G. Compatibilité physique par évaluation visuelle du salbutamol injectable lors de son administration en Y. Pharmactuel 2011 ; 44, 1 : 14-18
3249	Revue	Singh BM, Dedhiya MG, Dinunzio J, Chan P, Kupiec TC, Trissel LA, Laudano JB. Compatibility of ceftaroline fosamil for injection with selected drugs during simulated Y-site administration. Am J Health-Syst Pharm 2011 ; 68: 2163-2169.
3254	Revue	Housman S.T, Tessier P.R, Nicolau D.P, Kuti J.L. Physical compatibility of telavancin hydrochloride with select i.v. drugs during simulated Y-site administration Am J Health-Syst Pharm 2011 ; 68: 2265-2270.
3268	Revue	Beauregard N, Bertrand N, Dufour A, Blaizel O, Leclair G Physical compatibility of calcium gluconate and magnesium sulfate injections. Am J Health-Syst Pharm 2012 ;69: 98.
3301	Revue	Sayre B.E, Prettyman T, Kaushal G. Extended Stability of Magnesium Sulfate Infusions Prepared in Polyolefin Bags. Hosp Pharm 2012 ; 47, 4: 289-292.
3372	Revue	Hanci V, Ali Kiraz H, Ömür D, Ekin S, Uyan B, Yurtlu B.S. Precipitation in Gallipoli: Sugammadex / Amiodarone & Sugammadex / Dobutamine & Sugammadex / Protamine. Rev Bras Anesthesiol 2013 ; 63, 1: 163-166.
3408	Revue	Tollec S, Touzin K, Pelletier E, Forest J.M. Evaluation visuelle de la compatibilité physique de la naloxone avec d'autres médicaments intraveineux usuels. Pharmactuel 2013 ; 46, 1 : 16-21.
3526	Laboratoire	Clindamycin (Dalacin®) - Summary of Product Characteristics Pharmacia 2010
3546	Laboratoire	Cefamandole Flavelab - Résumé des caractéristiques du produit Panpharma SA 2007
3578	Laboratoire	Cisplatin - Summary of Product Characteristics Accord Healthcare 2011
3621	Laboratoire	Phosphate dipotassique - Résumé des caractéristiques du produit Renaudin 2008
3644	Laboratoire	Calcium gluconate® - Summary of Product Characteristics Hameln Pharmaceuticals 2010
3753	Laboratoire	Tedizolid phosphate (Sivextro®) - Summary of Product Characteristics Cubist Pharmaceuticals 2014
3767	Revue	Legris M.E, Lavoie A, Forrest J.M, Hildgen P. Compatibilité par évaluation visuelle du thiopental injectable lors de son administration en Y avec des médicaments usuels. Pharmactuel 2014 ; 47, 3 : 167-172.

3781	Revue	Humbert-Delaloye V, Berger-Gryllaki M, Voirol P, Testa B, Pannatier A Screening for physicochemical incompatibilities of intravenous drugs in intensive care units: the case of monobasic potassium phosphate and furosemide. EJHP 2015 ;22:1 56-58
3791	Poster	Sadou Yaye H, Burtet E, Hamel C, Aljhi R, Gard C, Tilleul P. Étude de la compatibilité physico-chimique du phloroglucinol injectable durant les mélanges au sein des tubulures en Y. Apifh Congress, Paris November 2014 2014
3824	Revue	Boudi S, Roy H, Forest JM, Leclair G. Compatibilité physique de l'association amoxicilline-acide clavulanique en injection avec plusieurs autres médicaments lors d'une administration en Y. Pharmactuel 2023 2023;56,3:91-98
3827	Poster	Ghazi I.M, Hamada Y, Nicolau D.P. Compatibility of tedizolid phosphate with selected intravenous drugs via simulated Y-site conditions. ASHP Midyear 2015
3828	Poster	Thabit A.K, Hamada Y, Nicolau D.P. Ceftozolane/tazobactam physical compatibility during simulated Y-site administration. ASHP Midyear 2015
3829	Poster	So W, Kim L, Thabit A.K, Nicolau D.P, Kuti J.L. Compatibility of isavanazonium sulfate during simulated Y-site administration. ASHP Midyear 2015
3838	Laboratoire	Magnesium Sulphate - Summary of Product Characteristics Martindale Pharmaceuticals Ltd 2007
3948	Revue	Bouchoud L, Fonzo-Christe C, Klingmüller M, Bonnabry P . Compatibility of Intravenous Medications With Parenteral Nutrition - In Vitro Evaluation. JPEN 2012 ;30. 416-424.
3964	Revue	Audet M.A, Forest E, Friciu M, Forest J.M, Leclair G. Compatibilité du citrate de caféine injectable avec plusieurs autres médicaments. Pharmactuel 2017 ; 50,1 : 27-33.
4055	Revue	Monogue M, Almarzoky Abuhussain S, Kuti J, Nicolau D. Physical compatibility of fosfomycin for injection with select i.v. drugs during simulated Y-site administration. Am J Health-Syst Pharm 2018 , 75, 1:36-44
4145	Revue	Asempta T.E, Avery L.M, Kidd J.M, Kuti J.L, Nicolau D.P. Physical compatibility of plazomicin with select i.v. drugs during simulated Y-site administration. Am J Health-Syst Pharm 2018 ;75,14:1048-1056
4154	Laboratoire	Bleomycin sulfate- Summary of Product Characteristics Accord Health Care 2018
4254	Revue	D'Huart E, Vigneron J, Demoré B. Physical Compatibility of Intravenous Drugs Commonly Used in Intensive Care Units: An Observational Study and Physical Compatibility Laboratory Tests on Anti-Infective Drugs Pharmaceutical Technology in Hospital Pharmacy 2019 ;4,1:29-40
4319	Revue	Lessard J-J, Caron E, Schérer H, Forest J-M, Leclair G. Compatibility of Y-site Injection of Meropenem Trihydrate With 101 Other Injectable Drugs. Hosp Pharm 2020 ; 55, 5: 332-337.
4389	Revue	Côté K, Correal F, Metras M.E, Friciu M, Forest J.M, Leclair G. Compatibilité physique des médicaments administrés en Y aux soins intensifs, en particulier la dexmédétomidine, le lévamisentan et la kétamine. Pharmactuel 2019 ;52,4:206-213
4428	Revue	Rashed S.M, Sweatman T.W, Thoma L, Hovinga C.A, Phelps S.J. Chemical Compatibility of Depacon® with Medications Frequently Administered by Intravenous Y-Site Delivery in Patients with Epilepsy or Head Trauma. J Pediatr Pharmacol Ther 2004 ; 9, 2: 126-132.

4433	Revue	Ghazi I.M, El Nekidy W.S, Sood A, Dulku A, Patel R, Patel K. Y-site Administration of Imipenem/Cilastatin/ Relebactam With Common Intravenous Medications Clin Ther 2020 ; 42, 3: 475-485.
4434	Revue	Avery L.M, Chen, I.H, Reyes, S, Nicolau, D.P, Kuti J.L. Assessment of the Physical Compatibility of Eravacycline and Common Parenteral Drugs During Simulated Y-site Administration. Clin Ther 2019 ; 41, 10: 2162-2170.
4457	Revue	Houlihan, S, Decarie, D, Benes, C, Cleve, R, Vidler M, Magee L.A, Ensom M.H.H, vonDadelszen P. Magnocaine: Physical Compatibility and Chemical Stability of Magnesium Sulphate and Lidocaine Hydrochloride in Prefilled Syringes. J Obstet Gynaecol Can 2016 ;38,10:936e944.
4524	Poster	Stucki C, Sautter A-M, Bonnabry P. Physical compatibility of the propofol emulsion with 33 drugs used in anaesthesiology. ESCP Symposium, Geneva, Switzerland 2009
4528	Revue	Lu J, Liu Q, Kupiec T, Vail H, Lunch L, Fam D, Vu N. Physical Compatibility of Cefiderocol with Selected Intravenous Drugs During Simulated Y-site Administration. Int J Pharm Compound 2021 ;25,1:52-61
4603	Revue	Vallée M, Barthélémy I, Friciu M, Pelletier E, Forest J.M, Benoit F, Leclair G. Compatibility of Lactated Ringer's Injection With 94 Selected Intravenous Drugs During Simulated Y-site Administration. Hosp Pharm 2021 ; 56, 4: 228-234.
4642	Poster	Larossa garcia M, Jimenez-Lozano I, Boix-Montanés A, Mallandrich Miret M, Clemente Bautista M, cabanas Poy M.J., Gorgas Torner Compatibilidad en Y de atosiban y farmacois habitualmente utilizados en obstetricia. SEFH Congress (Virtual) October 2021 2021
4650	Laboratoire	Ceftobiprole (Zevtera 500 mg powder for concentrate for solution for infusion.) Summary of Product Characteristics, Advanz Pharma updated 4 aug 2021. Advanz Pharma 2021
4698	Revue	Ayari G, D'Huart E, Vigneron J, Demoré B. Y-site compatibility of intravenous medications commonly used in intensive care units : laboratory tests on 75 mixtures involving nine main drugs. Pharmaceutical Technology in Hospital Pharmacy 2022
4720	Laboratoire	Nuzyra (amadacycline - Full prescribing infomation. Paratek Pharmaceuticals updated May 2021. Paratek Pharmaceuticals 2021
4742	Revue	Macoviciuc M, Nguyen C, Forest J-M, Leclair G. Compatibilité physique de l'acétaminophène injectable avec 102 autres médicaments lors d'une administration en Y. Pharmactuel 2022 ; 55, 4: 247-255.
4801	Revue	Ruiz V, Yuwei Shen Y, Abouelhassan Y, Fouad A, Nicolau D, Kuti J. Physical compatibility of sulbactam/durlobactam with select intravenous drugs during simulated Y-site administration. Am J Health-Syst Pharm 2024 ;51,1:



Dictionnaire

	électrolyte		Injectable
	Noms commerciaux		Stabilité des solutions
	Contenant		Molécule
	Concentration		Température
	Conservation		Durée de stabilité
	Biosimilaire		Données conflictuelles
	Bibliographie		Verre
	Chlorure de sodium 0,9%		Non précisée
	Jour	RL	Ringer lactate
	Polyvinyl chlorure		Aucun
	Polyolefine		A l'abri de la lumière
	Stabilité en mélange		Solvant
	Molécule		Lumière
	Heure		Glucose 5%
	NaCl 0,9% ou glucose 5%		Seringue polypropylène
	Compatibilités		Compatible
	Incompatibilité non précisée		Incompatible
	Précipitation immédiate		Turbidité en 1 heure
	Précipitation en 2 heures		Instabilité chimique
	Eau pour préparation injectable		Turbidité immédiate
	Précipitation en 1 heure		Précipitation en 4 heures
	Changement de couleur en 24 heures		Turbidité à 24 heures
	Nutrition parentérale (mélange ternaire)		NaHCO ₃
	Nutrition parentérale (mélange binaire)		Solvant spécifique
	Bibliographie		Dictionnaire